Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24026859)

1.

Neoadjuvant bevacizumab: surgical complications of mastectomy with and without reconstruction.

Kansal KJ, Dominici LS, Tolaney SM, Isakoff SJ, Smith BL, Jiang W, Brock JE, Winer EP, Krop IE, Golshan M.

Breast Cancer Res Treat. 2013 Sep;141(2):255-9. doi: 10.1007/s10549-013-2682-z. Epub 2013 Sep 13.

PMID:
24026859
2.

Does neoadjuvant bevacizumab increase surgical complications in breast surgery?

Golshan M, Garber JE, Gelman R, Tung N, Smith BL, Troyan S, Greenberg CC, Winer EP, Ryan P.

Ann Surg Oncol. 2011 Mar;18(3):733-7. doi: 10.1245/s10434-010-1366-8. Epub 2010 Sep 30.

PMID:
20882415
3.

Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction.

Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES.

Arch Surg. 2010 Sep;145(9):880-5. doi: 10.1001/archsurg.2010.163.

PMID:
20855759
4.

Surgical complications of skin sparing mastectomy and immediate prosthetic reconstruction after neoadjuvant chemotherapy for invasive breast cancer.

Donker M, Hage JJ, Woerdeman LA, Rutgers EJ, Sonke GS, Vrancken Peeters MJ.

Eur J Surg Oncol. 2012 Jan;38(1):25-30. doi: 10.1016/j.ejso.2011.09.005. Epub 2011 Oct 2.

PMID:
21963981
5.

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups.

N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065.

6.

Impact of neoadjuvant chemotherapy on breast reconstruction.

Hu YY, Weeks CM, In H, Dodgion CM, Golshan M, Chun YS, Hassett MJ, Corso KA, Gu X, Lipsitz SR, Greenberg CC.

Cancer. 2011 Jul 1;117(13):2833-41. doi: 10.1002/cncr.25872. Epub 2011 Jan 24.

7.

Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.

Rodgers M, Soares M, Epstein D, Yang H, Fox D, Eastwood A.

Health Technol Assess. 2011 May;15 Suppl 1:1-12. doi: 10.3310/hta15suppl1/01. Review.

8.

Neoadjuvant chemotherapy and short-term morbidity in patients undergoing mastectomy with and without breast reconstruction.

Abt NB, Flores JM, Baltodano PA, Sarhane KA, Abreu FM, Cooney CM, Manahan MA, Stearns V, Makary MA, Rosson GD.

JAMA Surg. 2014 Oct;149(10):1068-76. doi: 10.1001/jamasurg.2014.1076.

9.

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.

Clavarezza M, Turazza M, Aitini E, Saracchini S, Garrone O, Durando A, De Placido S, Bisagni G, Levaggi A, Bighin C, Restuccia E, Scalamogna R, Galli A, Del Mastro L.

Breast. 2013 Aug;22(4):470-5. doi: 10.1016/j.breast.2013.03.012. Epub 2013 May 1.

PMID:
23642526
10.

Mastectomy with immediate breast reconstruction after neoadjuvant chemotherapy and radiation therapy. A new option for patients with operable invasive breast cancer. Results of a 20 years single institution study.

Monrigal E, Dauplat J, Gimbergues P, Le Bouedec G, Peyronie M, Achard JL, Chollet P, Mouret-Reynier MA, Nabholtz JM, Pomel C.

Eur J Surg Oncol. 2011 Oct;37(10):864-70. doi: 10.1016/j.ejso.2011.07.009. Epub 2011 Aug 16.

PMID:
21843920
11.

Surgical outcome after neoadjuvant chemotherapy and bevacizumab: results from the GeparQuinto study (GBG 44).

Gerber B, von Minckwitz G, Eidtmann H, Rezai M, Fasching P, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Solbach C, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Nekljudova V, Loibl S, Untch M.

Ann Surg Oncol. 2014 Aug;21(8):2517-24. doi: 10.1245/s10434-014-3606-9. Epub 2014 Apr 18.

PMID:
24740826
12.

Influence of neoadjuvant chemotherapy on outcomes of immediate breast reconstruction.

Azzawi K, Ismail A, Earl H, Forouhi P, Malata CM.

Plast Reconstr Surg. 2010 Jul;126(1):1-11. doi: 10.1097/PRS.0b013e3181da8699.

PMID:
20595827
13.

Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.

Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA 3rd, Hainsworth JD.

Clin Breast Cancer. 2011 Oct;11(5):297-305. doi: 10.1016/j.clbc.2011.04.002. Epub 2011 May 5.

PMID:
21729666
14.

Immediate reconstruction after neoadjuvant chemotherapy: effect on adjuvant treatment starting and survival.

Gouy S, Rouzier R, Missana MC, Atallah D, Youssef O, Barreau-Pouhaer L.

Ann Surg Oncol. 2005 Feb;12(2):161-6. Epub 2005 Feb 4.

PMID:
15827797
15.

Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy.

Krueger EA, Wilkins EG, Strawderman M, Cederna P, Goldfarb S, Vicini FA, Pierce LJ.

Int J Radiat Oncol Biol Phys. 2001 Mar 1;49(3):713-21.

PMID:
11172953
16.

Immediate reconstruction with implants in women with invasive breast cancer does not affect oncological safety in a matched cohort study.

Eriksen C, Frisell J, Wickman M, Lidbrink E, Krawiec K, Sandelin K.

Breast Cancer Res Treat. 2011 Jun;127(2):439-46. doi: 10.1007/s10549-011-1437-y. Epub 2011 Mar 16.

PMID:
21409394
17.

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.

Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kühn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G.

J Clin Oncol. 2010 Apr 20;28(12):2024-31. doi: 10.1200/JCO.2009.23.8451. Epub 2010 Mar 22.

18.

Immediate breast reconstruction and high-dose chemotherapy.

Rey P, Martinelli G, Petit JY, Youssef O, De Lorenzi F, Rietjens M, Garusi C, Giraldo A.

Ann Plast Surg. 2005 Sep;55(3):250-4.

PMID:
16106161
19.

Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response.

Sánchez-Rovira P, Seguí MA, Llombart A, Aranda E, Antón A, Sánchez A, Lomas M, Jaén A, Fernández M, Porras I, Dalmau E, Morales S, de la Haba-Rodríguez J.

Clin Transl Oncol. 2013 Oct;15(10):810-7. doi: 10.1007/s12094-013-1006-4. Epub 2013 Feb 9.

20.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

Semiglazov V, Eiermann W, Zambetti M, Manikhas A, Bozhok A, Lluch A, Tjulandin S, Sabadell MD, Caballero A, Valagussa P, Baselga J, Gianni L.

Eur J Surg Oncol. 2011 Oct;37(10):856-63. doi: 10.1016/j.ejso.2011.07.003. Epub 2011 Aug 16.

PMID:
21843921
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk